Home Cart 0 Sign in  
X

[ CAS No. 5460-31-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 5460-31-1
Chemical Structure| 5460-31-1
Chemical Structure| 5460-31-1
Structure of 5460-31-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 5460-31-1 ]

Related Doc. of [ 5460-31-1 ]

Alternatived Products of [ 5460-31-1 ]

Product Details of [ 5460-31-1 ]

CAS No. :5460-31-1 MDL No. :MFCD00007241
Formula : C7H7NO3 Boiling Point : -
Linear Structure Formula :- InChI Key :GAKLFAZBKQGUBO-UHFFFAOYSA-N
M.W : 153.14 Pubchem ID :79579
Synonyms :

Calculated chemistry of [ 5460-31-1 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.14
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 42.25
TPSA : 66.05 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.74 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.36
Log Po/w (XLOGP3) : 2.11
Log Po/w (WLOGP) : 1.61
Log Po/w (MLOGP) : 0.61
Log Po/w (SILICOS-IT) : -0.36
Consensus Log Po/w : 1.07

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.46
Solubility : 0.535 mg/ml ; 0.0035 mol/l
Class : Soluble
Log S (Ali) : -3.13
Solubility : 0.114 mg/ml ; 0.000745 mol/l
Class : Soluble
Log S (SILICOS-IT) : -1.57
Solubility : 4.08 mg/ml ; 0.0267 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.64

Safety of [ 5460-31-1 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P501-P273-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330 UN#:2446
Hazard Statements:H301-H315-H319-H412 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 5460-31-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 5460-31-1 ]
  • Downstream synthetic route of [ 5460-31-1 ]

[ 5460-31-1 ] Synthesis Path-Upstream   1~18

  • 1
  • [ 5460-31-1 ]
  • [ 81382-45-8 ]
Reference: [1] Patent: EP1403255, 2004, A1,
  • 2
  • [ 5460-31-1 ]
  • [ 19500-02-8 ]
Reference: [1] Journal of the Chemical Society, 1930, p. 1699,1707
[2] Patent: WO2011/69951, 2011, A1,
[3] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 4, p. 1441 - 1449
  • 3
  • [ 603-83-8 ]
  • [ 5460-31-1 ]
Reference: [1] Chemistry - A European Journal, 2009, vol. 15, # 12, p. 2742 - 2746
[2] Chemische Berichte, 1884, vol. 17, p. 1959
[3] Chemische Berichte, 1904, vol. 37, p. 1021
[4] Tetrahedron, 1968, vol. 24, p. 6093 - 6109
  • 4
  • [ 95-48-7 ]
  • [ 5460-31-1 ]
  • [ 612-84-0 ]
  • [ 112036-07-4 ]
  • [ 112036-06-3 ]
Reference: [1] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1987, vol. 26, # 1-12, p. 272 - 273
[2] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1987, vol. 26, # 1-12, p. 272 - 273
[3] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1993, vol. 32, # 2, p. 266 - 274
[4] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1992, vol. 31, # 7, p. 464 - 466
[5] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1992, vol. 31, # 7, p. 464 - 466
  • 5
  • [ 606-20-2 ]
  • [ 5460-31-1 ]
Reference: [1] Chemische Berichte, 1904, vol. 37, p. 1021
  • 6
  • [ 18102-30-2 ]
  • [ 5460-31-1 ]
Reference: [1] Journal of the Chemical Society, 1915, vol. 107, p. 833
  • 7
  • [ 143359-98-2 ]
  • [ 5460-31-1 ]
Reference: [1] Journal of the Chemical Society, 1915, vol. 107, p. 833
  • 8
  • [ 861548-37-0 ]
  • [ 5460-31-1 ]
Reference: [1] Journal of the Chemical Society, 1915, vol. 107, p. 833
  • 9
  • [ 861609-40-7 ]
  • [ 5460-31-1 ]
  • [ 4837-88-1 ]
Reference: [1] Journal of the Chemical Society, 1915, vol. 107, p. 833
[2] Journal of the Chemical Society, 1915, vol. 107, p. 833
  • 10
  • [ 7664-93-9 ]
  • [ 603-83-8 ]
  • [ 5460-31-1 ]
Reference: [1] Chemische Berichte, 1884, vol. 17, p. 1959
  • 11
  • [ 5460-31-1 ]
  • [ 74-88-4 ]
  • [ 4837-88-1 ]
Reference: [1] European Journal of Medicinal Chemistry, 2008, vol. 43, # 12, p. 2677 - 2687
[2] Heterocycles, 1981, vol. 16, # 7, p. 1119 - 1124
[3] Patent: WO2011/69951, 2011, A1, . Location in patent: Page/Page column 61
[4] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 4, p. 1441 - 1449
  • 12
  • [ 5460-31-1 ]
  • [ 77-78-1 ]
  • [ 4837-88-1 ]
Reference: [1] Journal of the Chemical Society, 1932, p. 1792,1795
[2] Journal of the Chemical Society, 1915, vol. 107, p. 833
[3] Helvetica Chimica Acta, 1924, vol. 7, p. 698
[4] Journal of the Chemical Society, 1930, p. 1699,1707
[5] Tetrahedron, 1968, vol. 24, p. 6093 - 6109
  • 13
  • [ 861609-40-7 ]
  • [ 5460-31-1 ]
  • [ 4837-88-1 ]
Reference: [1] Journal of the Chemical Society, 1915, vol. 107, p. 833
[2] Journal of the Chemical Society, 1915, vol. 107, p. 833
  • 14
  • [ 5460-31-1 ]
  • [ 53967-73-0 ]
Reference: [1] Journal of the Chemical Society, 1932, p. 1792,1795
  • 15
  • [ 5460-31-1 ]
  • [ 53222-92-7 ]
YieldReaction ConditionsOperation in experiment
99% With palladium 10% on activated carbon; hydrogen In methanol at 20℃; for 24 h; A stirred mixture of 2-Methyl-3-nitrophenol 5 (2.0g, 13.1mmol) in MeOH (50mL) at room temperature was treated with 10wtpercent palladium on charcoal (100mg). Hydrogen gas was passed through the mixture for 24h, and then the palladium on charcoal was removed by filtration through Celite. The filtrate was concentrated in vacuo, and was obtained as darked solid (1.62g, 99percent). 1H NMR (CD3OD, δ=3.31ppm, 400MHz): 6.77–6.73, (t, 1H), 6.29–6.27 (d, 1H), 6.22–6.20 (d, 1H), 2.02 (s, 3H). 13C NMR (CD3OD, δ=49.00ppm, 100MHz): 156.7, 147.5, 127.2, 110.9, 108.8, 106.7, 9.2. HRMS (ESI) m/z: Anal. calcd. for [M+H]+ C7H10NO: 124.0757; found 124.0759.
99% With palladium 10% on activated carbon; hydrogen In methanol at 20℃; for 24 h; 2-methyl-3-nitrophenol (2.0 g, 13.1 mmol) was dissolved in methanol (50 mL) at room temperature and then 10 wtpercent palladium on charcoal (100 mg) . The reaction mixture was stirred under hydrogen gas for 24 hours, then 10percent by weight palladium / charcoal was filtered through celite. The filtrate was concentrated in vacuo to give the desired compound (1.62 g, 99percent yield) as a solid.
Reference: [1] Patent: US5952362, 1999, A,
[2] Patent: EP887346, 1998, A2,
[3] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 87 - 100
[4] Patent: KR2017/31307, 2017, A, . Location in patent: Paragraph 0182-0184
[5] Journal of Medicinal Chemistry, 2010, vol. 53, # 5, p. 1964 - 1978
[6] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 23, p. 7170 - 7174
[7] Chemische Berichte, 1884, vol. 17, p. 1959
[8] Chemische Berichte, 1904, vol. 37, p. 1021
[9] Journal of Organic Chemistry, 1989, vol. 54, # 15, p. 3740 - 3744
[10] Chemical Communications, 2005, # 15, p. 2026 - 2028
[11] Patent: US4579951, 1986, A,
  • 16
  • [ 5460-31-1 ]
  • [ 53600-33-2 ]
Reference: [1] Journal of the Chemical Society, 1932, p. 1792,1795
  • 17
  • [ 5460-31-1 ]
  • [ 100-39-0 ]
  • [ 20876-37-3 ]
YieldReaction ConditionsOperation in experiment
100% With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 3 h; 41.5 g (300 mmol) of potassium carbonate and 200 ml of N,N-dimethylformamide were added to 30.6 g (200 mmol) of 2-methyl-3-nitrophenol.
Then, 23.8 ml (200 mmol) of benzyl bromide was added thereto in an argon stream with stirring and the mixture was stirred at room temperature for 3 hours.
After the reaction was completed, the reaction solution was poured into 1000 ml of water and the mixture was extracted with 800 ml of toluene and 500 ml of the same twice.
The organic layer was successively washed with water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated under reduced pressure, whereby 49.3 g of the title compound was obtained as yellow powder (yield: quantitative).
Rf value: 0.48 (n-hexane:ethyl acetate=4:1 (v/v))
Mass spectrum (CI, m/z): 244 (M++1)
1H-NMR spectrum (CDCl3, δppm): 2.42 (s, 3H), 5.13 (s, 2H), 7.08-7.11 (m, 1H), 7.21-7.27 (m, 1H), 7.32-7.44 (m, 6H)
87% With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 3 h; A mixture of 2-methyl-3-nitrophenol (672 mg, 4.4 mmol), cesium carbonate (2.1 g, 6.44 mmol), and benzyl bromide (751 mg, 4.4 mmol) in DMF (6 mL) was stirred at room temperature for 3 h. The reaction mixture was poured into ice water. The light yellow precipitation was filtered off, washed several times with water, and dried, to provide 1-nitro-2-methyl-3-[(phenylmethyl)oxy]benzene (930 mg, 87percent yield). (at)HNMR (400 MHz, d4-methanol): 8 7.47 (d, 1H), 7.45 (s, 1H), 7.40 (s, 1H), 7.39 (d, 1H), 7.37 (d, 1H), 7.34 (m, 1H), 7.32 (s, 1H), 7.29 (d, 1H), 4.90 (s, 2H), 2.35 (s, 3H).
8.6 g With potassium carbonate In acetonitrile at 90℃; for 2 h; To a 500-mL 3-necked round-bottom flask was placed a solution of 2-methyl-3-nitrophenol (10 g,65.30 mmol) and K2C03 (13 g,94.06 mmol) in CH3CN (100 mL) then BnBr (13 g,76.01 mmol) was added. The reaction was stirred at 90°C for 2 h,cooled to rt,filtered,and concentrated under reduced pressure. Thecrude product was purified by column chromatography eluting with EtOAc/petroleum ether (1:9) affording 8.6 g of the title compound as a yellow oil.
Reference: [1] Patent: US2009/12123, 2009, A1, . Location in patent: Page/Page column 9-10
[2] Patent: WO2005/117909, 2005, A2, . Location in patent: Page/Page column 119
[3] Journal of the Chemical Society, 1948, p. 1605,1608
[4] Heterocycles, 1981, vol. 16, # 7, p. 1119 - 1124
[5] Patent: EP1870099, 2007, A1, . Location in patent: Page/Page column 14
[6] Patent: WO2017/62581, 2017, A1, . Location in patent: Paragraph 0209
  • 18
  • [ 5460-31-1 ]
  • [ 100-44-7 ]
  • [ 20876-37-3 ]
Reference: [1] Archiv der Pharmazie, 1988, vol. 321, # 8, p. 487 - 489
[2] Organic Syntheses, 1985, vol. 63, p. 214 - 214
[3] Tetrahedron, 1968, vol. 24, p. 6093 - 6109
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 5460-31-1 ]

Aryls

Chemical Structure| 99-53-6

[ 99-53-6 ]

2-Methyl-4-nitrophenol

Similarity: 0.96

Chemical Structure| 2423-71-4

[ 2423-71-4 ]

2,6-Dimethyl-4-nitrophenol

Similarity: 0.93

Chemical Structure| 180628-74-4

[ 180628-74-4 ]

3-(Hydroxymethyl)-5-nitrophenol

Similarity: 0.91

Chemical Structure| 20876-37-3

[ 20876-37-3 ]

1-Benzyloxy-2-methyl-3-nitrobenzene

Similarity: 0.90

Chemical Structure| 5804-49-9

[ 5804-49-9 ]

(2-Methoxy-5-nitrophenyl)methanol

Similarity: 0.89

Nitroes

Chemical Structure| 99-53-6

[ 99-53-6 ]

2-Methyl-4-nitrophenol

Similarity: 0.96

Chemical Structure| 2423-71-4

[ 2423-71-4 ]

2,6-Dimethyl-4-nitrophenol

Similarity: 0.93

Chemical Structure| 180628-74-4

[ 180628-74-4 ]

3-(Hydroxymethyl)-5-nitrophenol

Similarity: 0.91

Chemical Structure| 20876-37-3

[ 20876-37-3 ]

1-Benzyloxy-2-methyl-3-nitrobenzene

Similarity: 0.90

Chemical Structure| 5804-49-9

[ 5804-49-9 ]

(2-Methoxy-5-nitrophenyl)methanol

Similarity: 0.89